Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Seward

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 14, 2006
Elective liver transplantation for the treatment of classical maple syrup urine diseaseK A Strauss, G V Mazariegos, R Sindhi, et al.
ACS Medicinal Chemistry Letters|September 27, 2017
Design of Selective Benzoxazepin PI3Kδ Inhibitors Through Control of Dihedral AnglesBrian S Safina, Richard L Elliott, Andrew K Forrest, et al.
Cancer|April 26, 2017
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumorsKathleen N Moore, Hossein Borghaei, David M O'Malley, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|July 5, 2021
Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot StudyTatyana A Grushko, Virginia L Filiaci, Anthony G Montag, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2020
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid TumorsRaffit Hassan, George R Blumenschein, Kathleen N Moore, et al.
Gynecologic Oncology|August 21, 2016
Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysisKathleen N Moore, James J Java, Katrina N Slaughter, et al.
Bioorganic & Medicinal Chemistry Letters|July 23, 2013
Identification of GNE-293, a potent and selective PI3Kδ inhibitor: navigating in vitro genotoxicity while improving potency and selectivityBrian S Safina, Zachary K Sweeney, Jun Li, et al.
Journal of Medicinal Chemistry|July 19, 1996
N-heteroaryl-2-phenyl-3-(benzyloxy)piperidines: a novel class of potent orally active human NK1 antagonistsT Ladduwahetty, R Baker, M A Cascieri, et al.
Journal of Medicinal Chemistry|August 11, 2012
Potent and highly selective benzimidazole inhibitors of PI3-kinase deltaJeremy M Murray, Zachary K Sweeney, Bryan K Chan, et al.
Future Oncology (London, England)|June 19, 2023
ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancerThomas J Herzog, John L Hays, Joyce N Barlin, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 14, 2006
Elective liver transplantation for the treatment of classical maple syrup urine diseaseK A Strauss, G V Mazariegos, R Sindhi, et al.
ACS Medicinal Chemistry Letters|September 27, 2017
Design of Selective Benzoxazepin PI3Kδ Inhibitors Through Control of Dihedral AnglesBrian S Safina, Richard L Elliott, Andrew K Forrest, et al.
Cancer|April 26, 2017
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumorsKathleen N Moore, Hossein Borghaei, David M O'Malley, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|July 5, 2021
Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot StudyTatyana A Grushko, Virginia L Filiaci, Anthony G Montag, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2020
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid TumorsRaffit Hassan, George R Blumenschein, Kathleen N Moore, et al.
Gynecologic Oncology|August 21, 2016
Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysisKathleen N Moore, James J Java, Katrina N Slaughter, et al.
Bioorganic & Medicinal Chemistry Letters|July 23, 2013
Identification of GNE-293, a potent and selective PI3Kδ inhibitor: navigating in vitro genotoxicity while improving potency and selectivityBrian S Safina, Zachary K Sweeney, Jun Li, et al.
Journal of Medicinal Chemistry|July 19, 1996
N-heteroaryl-2-phenyl-3-(benzyloxy)piperidines: a novel class of potent orally active human NK1 antagonistsT Ladduwahetty, R Baker, M A Cascieri, et al.
Journal of Medicinal Chemistry|August 11, 2012
Potent and highly selective benzimidazole inhibitors of PI3-kinase deltaJeremy M Murray, Zachary K Sweeney, Bryan K Chan, et al.
Future Oncology (London, England)|June 19, 2023
ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancerThomas J Herzog, John L Hays, Joyce N Barlin, et al.
Pageof 6